Ceapro Inc V.CZO

5 year return

[prophetoffactz]

S&P Biotech ETF down 18.3%.
CZO down 5.95%.

That's what a biotech bear market does.
CZO's base business has kept the company viable in this historic bear market for biotech.
 
Many small scap biotech stocks have been abandoned, are going bankrupt, or are being restructured now. This creates an opportunity for companies like CZO. CZO has been investigating reverse takeovers to list on NASDAQ. Of the many biotech companies that have been abandoned which one could add cash, revenue, pipeline, and build scale as CZO's pipeline reaches key strategic milestones from the 5X and 10X PGX scale-up and potential licensing deal, to the avenanthramide clinical trial results, to the year beta glucan fibrosis trial, to the wound healing clinical trials.

[boazklinghorn]

Seriously dude just stop talking now. Like Gilles you have an excuse for every failure. Hmmm? As I have pointed out there are endless examples of companies that have succeeded spectacularily in the last five years it is cold comfort to shareholders to say "hey cheer up, It could have been worse". I am struck I must say by the pervasive zietgiest the pervades Ceapro and eminates from the

[prophetoffactz]

"I am struck I must say by the pervasive zietgiest the pervades Ceapro and eminates from the top that failure is acceptable that we can always just drop any project and move on to the next big thing..." The opposite is the case and in an exceptional way. Rarely will you find a venture company that hasn't dropped its projects over the course of a decade but only stregthened them like